Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer

Journal of Clinical Oncology

Volumn 14, Issue 11, 1996, Pages 2893-2900

  Critz, F A ^a   Levinson, A K ^a   Williams, W H ^a   Holladay, D A ^a  

^a DeKalb Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE;

EID: 0029850056     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.11.2893     Document Type: Article

References (32)

1. Elgamal A, Billen J, Van de Voorde W, et al: Extra prostatic sources of PSA, does it infer the subjective biochemical recurrence after radical prostatectomy. Proc Am Urol Assoc 153:518A, 1995 (abstr 1157)
2. Oesterling J, Martin S, Bergstralh E, et al: The periurethral glands do not have a clinically significant effect on the serum PSA concentration. Proc Am Urol Assoc 153:518A, 1995 (abstr 1158)
3. Partin A, Oesterling J: The clinical usefulness of prostate specific antigen: Update 1994. J Urol 152:1358-1368, 1994
4. Takayama T, Vessella R, Lange P: Newer applications of serum prostate-specific antigen in the management of prostate cancer. Semin Oncol 21:542-553, 1994
5. Partin A, Pound C, Clemens J, et al: Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 20:713-725, 1995
6. Trapasso J, deKernion J, Smith R, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821-1825, 1994
7. Frazier H, Robertson J, Humphrey P, et al: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 149:516-518, 1993
8. Catalona W, Smith D: 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837-1842, 1994
9. Takayama T, Vessella R, Brawer M, et al: The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. J Urol 150:374-378, 1993
10. Critz F, Tarlton R, Holladay D: Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. Cancer 75:2383-2391, 1995
11. Tibbs MK, Zietman AL, Dallow KC, et al: Biochemical outcome following external beam radiation therapy for T1-2 prostate carcinoma: The importance of achieving an undetectable nadir PSA. Int J Radiat Oncol Biol Phys 32:230, 1995 (abstr 1016)
12. Zagars G, Pollack A: Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urology 45:476-483, 1995
13. Zelefsky M, Leibel S, Wallner K, et al: Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J Clin Oncol 13:459-463, 1995
14. Hanks G, Perez C, Kozar M, et al: PSA conformation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys 30:289-292, 1994
15. Hanks G, Lee W, Schultheiss T: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 154:1-8, 1995
16. Zagars GK, Sherman NE, Babaian RT: Prostate specific antigen and external beam radiation therapy in prostate cancer. Cancer 67:412-419, 1991
17. Kuban D, El-Mahdi A, Schellhammer P: Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 32:307-316, 1995
18. Lu-Yao G, Greenberg E: Changes in prostate cancer incidence and treatment in USA. Lancet 343:251-254, 1994
19. Stamey T, Ferrari M, Schmid H: The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steep increasing values characterize 80% of patients. J Urol 150:1856-1859, 1993
20. Stamey T, Ferrari M, Schmid H: RE: The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J Ural 152:494, 1994 (letter)
21. Gaeta J, Asiwartham J, Miller G, et al: Histologic grading of primary prostatic cancer: A new approach to an old problem. J Urol 123:689-693, 1980
22. Mostofi F: Grading of prostatic carcinoma. Cancer Chemother Rep 59:111-116, 1975
23. Gottesman JE, Tesh DG, Weissman WD: Failure of open radioactive 125 iodine implantation to control localized prostate cancer: A study of 41 patients. J Urol 146:1317-1320, 1991
24. Balter JM, Sandier HM, Lam K, et al: Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys 31:113-118, 1995
25. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993
26. Gehan EA: Estimating survival functions from the life table. J Chronic Dis 21:629-644, 1969
27. Peto R, Peto J: Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 135:185-206, 1972
28. Cox D: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
29. Kalbfleisch J, Prentice R: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, pp 70-118
30. Fleiss J: Statistical Methods for Rates and Proportions (ed 2). New York, NY, Wiley, 1981
31. Kavadi V, Zagars G, Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int J Radiat Oncol Biol Phys 30:279-287, 1994
32. Goad J, Chang S, Ohori M, et al: PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 20:727-736, 1993